MedTrace Logo

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

NCT02976129 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2021-12-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease (CD).

Conditions

Interventions

DRUG

V565

Daily dosing of V565 three times a day orally for 6 weeks

DRUG

Placebo

Daily dosing of placebo three times a day orally for 6 weeks

Sponsors & Collaborators

  • VHsquared Ltd.

    lead INDUSTRY

Principal Investigators

  • Suhail Nurbhai, MBChB MRCP · VHsquared Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-03-08
Completion
2019-03-08

Countries

  • United States
  • Austria
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Netherlands
  • Norway
  • Poland
  • Serbia
  • Slovakia
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02976129 on ClinicalTrials.gov